STAAR Surgical (NASDAQ:STAA) Receives $42.83 Consensus Price Target from Analysts

STAAR Surgical (NASDAQ:STAA - Get Free Report) has earned a consensus rating of "Hold" from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $42.83.

STAA has been the subject of several recent analyst reports. Stephens raised shares of STAAR Surgical to a "hold" rating in a report on Monday, December 2nd. Canaccord Genuity Group cut their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a "hold" rating for the company in a research report on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a research report on Thursday, October 31st.

Insider Activity

In other news, major shareholder Broadwood Partners, L.P. acquired 23,000 shares of the firm's stock in a transaction dated Wednesday, December 18th. The shares were bought at an average price of $24.33 per share, with a total value of $559,590.00. Following the acquisition, the insider now owns 10,848,631 shares of the company's stock, valued at $263,947,192.23. This trade represents a 0.21 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Van ECK Associates Corp raised its stake in shares of STAAR Surgical by 12.7% in the 3rd quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier's stock valued at $129,000 after buying an additional 393 shares in the last quarter. Sei Investments Co. raised its position in STAAR Surgical by 2.7% in the second quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier's stock worth $718,000 after purchasing an additional 394 shares in the last quarter. Creative Planning raised its position in STAAR Surgical by 8.0% in the third quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier's stock worth $205,000 after purchasing an additional 408 shares in the last quarter. LMR Partners LLP lifted its stake in STAAR Surgical by 2.2% during the third quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier's stock worth $1,290,000 after purchasing an additional 743 shares during the period. Finally, Arcadia Investment Management Corp MI acquired a new stake in STAAR Surgical during the third quarter valued at approximately $37,000. 96.70% of the stock is owned by institutional investors.

STAAR Surgical Price Performance

STAA traded down $1.21 on Monday, hitting $23.33. The company had a trading volume of 1,095,667 shares, compared to its average volume of 709,222. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 53.02 and a beta of 0.63. The company's fifty day moving average price is $26.69 and its 200 day moving average price is $33.13. STAAR Surgical has a 1-year low of $22.40 and a 1-year high of $52.68.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.